Phase Ib Trial of Enzalutamide in Combination With Radiation Therapy and LHRH Agonist Therapy in the Management of Intermediate and High-Risk Prostate Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Oct 2019
Price : $35 *
At a glance
- Drugs Enzalutamide (Primary) ; Goserelin; Leuprorelin; Leuprorelin
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 27 Sep 2019 Planned End Date changed from 1 Jan 2020 to 1 Jan 2040.
- 09 Apr 2019 Planned End Date changed from 1 Jan 2019 to 1 Jan 2020.
- 31 Aug 2018 Biomarkers information updated